Osimertinib (Tagrisso) improves survival in people with non-small cell lung cancer with EGFR mutations, updated clinical trial results show. People treated with osimertinib lived longer than those treated with earlier-generation EGFR-targeted drugs.
from Cancer Currents: An NCI Cancer Research Blog https://ift.tt/2PfLmFI
from Cancer Currents: An NCI Cancer Research Blog https://ift.tt/2PfLmFI